Here are the 10-K annual reports from Actinium Pharmaceuticals, Inc (ATNM) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ATNM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATNM filings page.
Actinium Pharmaceuticals, Inc. files its annual report describing a clinical‑stage radiopharmaceutical business focused on targeted radiotherapies for solid tumors and blood cancers. Lead programs include ATNM‑400 for prostate, lung and breast cancer, Actimab‑A for myeloid malignancies and immuno‑oncology, and conditioning agents Iomab‑B and Iomab‑ACT for transplants and cell therapies.
The company highlights extensive preclinical data, late‑stage hematology assets with FDA‑aligned Phase 2/3 designs, and plans for a cGMP manufacturing facility expected operational in the second half of 2026. Actinium reports a net loss of $33.9 million in 2025, an accumulated deficit of $409.7 million, and 31,374,994 common shares outstanding as of March 30, 2026.